Akums Drugs & Pharmaceuticals Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Akums Drugs & Pharmaceuticals Ltd. - overview
Established
2004
Location
New Delhi, Delhi, India
Primary Industry
Pharmaceuticals
About
Based in India, Akums Drugs & Pharmaceuticals Ltd. is a leading Contract Development and Manufacturing Organization (CDMO) specializing in pharmaceuticals, nutraceuticals, and cosmetics, providing comprehensive services to a global clientele. Founded in 2004 in New Delhi, India, Akums Drugs & Pharmaceuticals Ltd. operates as a Contract Development and Manufacturing Organization (CDMO), focusing on the production of a variety of pharmaceutical formulations.
The company has not reported any significant pivots in its business strategy. The founders, Sandeep Jain and Sanjeev Jain, established the firm to cater to the growing demand for pharmaceutical manufacturing services. In July 2024, Akums raised USD 400. 00 mn in an LP Direct round from investors, including Abu Dhabi Investment Authority, bringing the total amount raised to USD 400.
00 mn with three deals recorded to date. Akums Drugs and Pharmaceuticals Ltd. stands as a prominent Contract Development and Manufacturing Organization (CDMO) in India, specializing in a wide array of pharmaceutical, nutraceutical, and cosmetic products. Their core offerings include the production of Active Pharmaceutical Ingredients (API), various dosage forms such as tablets, capsules, injectables, soft gels, syrups, and topicals, as well as nutraceuticals and cosmeceuticals.
These products are designed to address diverse healthcare needs, ranging from chronic conditions like hypertension and type 2 diabetes to wellness supplements and skincare solutions. The company serves a global client base, collaborating with over 1,500 pharmaceutical companies, and distributes its formulations primarily in markets across India, Europe, and the United States, ensuring compliance with international regulatory standards. Akums’ commitment to quality and innovation has solidified its reputation as a trusted partner in the healthcare sector, delivering products that enhance patient care and improve health outcomes. Akums Drugs and Pharmaceuticals Ltd.
generates revenue through a structured model that emphasizes partnerships and direct transactions with pharmaceutical companies. The company engages in B2B relationships, where large-scale orders are fulfilled for various clients, including leading healthcare brands. Transactions typically involve custom manufacturing agreements, where Akums produces specific formulations tailored to client specifications. Flagship products include Dapagliflozin-Pioglitazone tablets and Hydroxyurea Oral Suspension, among others.
For the year 2024, the company reported a revenue of USD 504. 73 mn and an EBITDA of USD 14. 37 mn, derived from production contracts negotiated based on volume, complexity, and regulatory requirements, ensuring consistent quality and timely delivery. In July 2024, Akums Drugs & Pharmaceuticals Ltd.
successfully completed an IPO, raising INR 18. 567 billion by selling 96. 18 million shares on the BSE under the ticker symbol "AKUM". The capital raised will be allocated towards developing new pharmaceutical products and expanding into international markets, particularly in Europe and North America, by the end of 2025.
Current Investors
Abu Dhabi Investment Authority, Quadria Capital Investment Management
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.akums.in
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Akums Drugs & Pharmaceuticals Ltd. - timeline of key events
Akums Drugs & Pharmaceuticals Ltd. - financials
| Fiscal Year Ended | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 7,939,537,398 | 8,966,357,072 | 14,642,694,617 | 16,509,143,452 | 18,634,812,000 | 15,542,071,000 | 20,082,579,318 | 241,415.6 | 27,226,294,000 | - | - | - |
| % Revenue Growth (YoY) | - | 12.9% | 63.3% | 12.7% | 12.9% | (16.6%) | 29.2% | (100.0%) | 11277669.1% | - | - | - |
| EBITDA (USD) | 1,205,206,982 | 1,455,844,336 | 1,289,243,072 | 1,469,548,836 | 2,018,746,000 | 2,113,673,000 | 2,013,500,172 | 19,326 | 2,427,025,000 | - | - | - |
| Operating Income (USD) | 1,077,260,200 | 1,312,302,223 | 978,919,741 | 1,085,537,063 | 1,561,770,000 | 1,597,946,000 | 1,453,864,614 | 12,657.9 | 1,728,620,000 | - | - | - |
| Operating Margin | 13.6% | 14.6% | 6.7% | 6.6% | 8.4% | 10.3% | 7.2% | 5.2% | 6.3% | - | - | - |
| % EBITDA Margin | 15.2% | 16.2% | 8.8% | 8.9% | 10.8% | 13.6% | 10.0% | 8.0% | 8.9% | - | - | - |
| NET Income (USD) | 830,810,690 | 1,056,948,408 | 377,819,240 | 445,352,234 | 955,402,000 | 904,932,000 | 680,413,849 | 4,365.4 | 1,234,363,000 | - | - | - |
| % Net Margin | 10.5% | 11.8% | 2.6% | 2.7% | 5.1% | 5.8% | 3.4% | 1.8% | 4.5% | - | - | - |
Akums Drugs & Pharmaceuticals Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Completed | Akums Drugs & Pharmaceuticals Ltd. | - | ||||||||
| IPO | Completed | Akums Drugs & Pharmaceuticals Ltd. | - | ||||||||
| Buyout | Completed | Akums Drugs & Pharmaceuticals Ltd. | - |
Displaying 1 - 3 of 3
Akums Drugs & Pharmaceuticals Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.